BDRXBiodexa Pharmaceuticals Plc

Nasdaq midatechpharma.com


$ 2.33 $ 1.06 (83.46 %)    

Tuesday, 21-May-2024 15:59:49 EDT
QQQ $ 454.82 $ 0.89 (0.2 %)
DIA $ 398.57 $ 0.68 (0.17 %)
SPY $ 530.36 $ 1.30 (0.25 %)
TLT $ 91.26 $ 0.47 (0.52 %)
GLD $ 225.37 $ -0.33 (-0.15 %)
$ 2.33
$ 2.24
$ 0.00 x 0
$ 0.00 x 0
$ 1.97 - $ 2.94
$ 0.67 - $ 16.32
125,654,905
na
2.77B
$ 1.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 whats-going-on-with-biodexa-pharmaceuticals-stock

Biodexa Pharmaceuticals (NASDAQ:BDRX) stock is trading higher. The company on Tuesday announced progress towards the treatment ...

Core News & Articles
Market-Moving News for May 21st
05/21/2024 12:42:13

BDRX: 110% | Biodexa Pharmaceuticals Presents Phase 2 Clinical Trial Results Of Its Newly-Licensed eRapa In Familial Adenomatou...

 biodexa-pharmaceuticals-presents-phase-2-clinical-trial-results-of-its-newly-licensed-erapa-in-familial-adenomatous-polyposis-scheduled-for-presentation-at-the-2024-digestive-disease-week-annual-meeting-reports-overall-83-non-progression-rate-at-6-months

Biodexa Pharmaceuticals PLC("Biodexa" or the "Company")Positive Statistically Significant Phase 2 Clinical Tria...

 biodexas-licensor-emtora-to-announce-phase-2-clinical-trial-results-of-erapa-in-familial-adenomatous-polyposis-to-be-presented-at-prestigious-2024-digestive-disease-week-annual-meeting

Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Pres...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION